Personalized Medicine and Proteomics: Lessons from Non-Small Cell Lung Cancer
- 17 July 2007
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 6 (8), 2925-2935
- https://doi.org/10.1021/pr070046s
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2005
- Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancerLung Cancer, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- The epidemiology of interstitial lung disease and its association with lung cancerBritish Journal of Cancer, 2004
- Regulation of an ATG7 - beclin 1 Program of Autophagic Cell Death by Caspase-8Science, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Lung Cancer and Cryptogenic Fibrosing AlveolitisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.American Journal of Respiratory and Critical Care Medicine, 1997
- Iung cancer associated with usual interstitial pneumoniaPathology International, 1995